What is the primary purpose of using erythropoiesis-stimulating agents in patients with chronic kidney disease?

The primary purpose of using erythropoiesis-stimulating agents, such as erythropoietin, in patients with chronic kidney disease is to stimulate red blood cell production. In chronic kidney disease, the kidneys are less able to produce erythropoietin, a hormone that signals the bone marrow to produce red blood cells. As a result, patients often experience anemia due to decreased red blood cell levels. By administering erythropoiesis-stimulating agents, healthcare providers can effectively counteract the anemia associated with kidney disease, thereby improving the patient's overall oxygen-carrying capacity and energy levels.

This approach specifically targets the problem of anemia rather than addressing other potential complications of chronic kidney disease, such as blood pressure management or fluid retention, making the stimulation of red blood cell production the correct and most relevant purpose of these agents in this context.